Friday 04 December 2020, Royal Marsden Hospital London
Level: Advanced
Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine’s other courses
Description: This course covers a wide range of licensed and experimental cancer treatments for solid tumours, explaining their mechanism of action at a molecular and cellular level. It also contains detailed information on mechanisms of drug resistance and discusses the future of personalised cancer medicine.
To book, contact: conferenceteam@rmh.nhs.uk Tel. 020 7808 2922
Programme
Targeted cancer treatments: the current landscape
- Where have we got to?
- Hallmarks of cancer cells – choose your target
- Cancer and the immune system
The main classes of current targeted treatments:
- Monoclonal antibody (mAb) technology
- Small molecule kinase inhibitors
Immunotherapy
- Checkpoint inhibitors
- CAR T cell therapy
- Peptide vaccines and oncolytic viruses
Targeting cell communication pathways
- Inhibitors of EGFR and HER2
- PI3K, AKT & mTOR inhibitors
- B-RAF & MEK inhibitors
- Drug resistance mechanisms
Angiogenesis, PARP and CDK inhibitors
- VEGFR/angiogenesis inhibitors
- PARP inhibitors
- CDK inhibitors for hormone-sensitive breast cancer
Biomarkers and personalised cancer treatment
- The use of biomarkers to select patients for trials and treatments for patients
- Progress in biomarkers for checkpoint inhibitors